Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1,206,888 | $802,879 | $229,347 | $874 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Cost of Goods Sold | $77,057 | $15,201 | $0 | $0 |
| Gross Profit | $1,129,831 | $787,678 | $229,347 | $874 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| R&D Expenses | $499,535 | $414,749 | $357,485 | $241,371 |
| G&A Expenses | $332,991 | $259,469 | $210,630 | $102,760 |
| SG&A Expenses | $1,060,731 | $774,659 | $390,232 | $141,724 |
| Sales & Mktg Exp. | $727,740 | $515,190 | $179,603 | $38,964 |
| Other Operating Expenses | $0 | $20,212 | $6,085 | $0 |
| Operating Expenses | $1,514,228 | $1,209,620 | $753,802 | $383,095 |
| Operating Income | -$384,397 | -$421,942 | -$524,456 | -$379,720 |
| % Margin | -31.9% | -52.6% | -228.7% | -43,446.2% |
| Other Income/Exp. Net | -$72,620 | $5,392 | $9,468 | -$53,930 |
| Pre-Tax Income | -$457,017 | -$409,417 | -$513,373 | -$436,151 |
| Tax Expense | $9,168 | $2,851 | -$3,836 | $360 |
| Net Income | -$466,185 | -$412,268 | -$509,537 | -$436,511 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| Weighted Avg Shares Out | 26,836 | 26,511 | 25,415 | 22,437 |
| Weighted Avg Shares Out Dil | 26,836 | 26,511 | 25,415 | 22,437 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29,095 | $50,195 | $102 | $547 |
| Interest Expense | $73,199 | $12,526 | $7,108 | $393 |
| Depreciation & Amortization | $16,594 | $12,913 | $34,433 | $2,823 |
| EBITDA | -$367,803 | -$388,817 | -$471,832 | -$379,398 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |